Restoring sensitivity to targeted therapies

from pharmaphorum Podcast · host pharmaphorum

In this new episode of the mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Simon Powell, CEO of Ribonexus, a new company put together to develop and ultimately commercialise long-standing research programmes from Gustav Roussy, Institut Curie, the University of Strasbourg, and Pierre Fabre, to develop drugs that overcome tumour resistance to existing drug treatments.

Episode metadata supplied by the publisher feed · Published Apr 14, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Restoring sensitivity to targeted therapies

0:00 19:59

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of pharmaphorum Podcast?

This episode is 19 minutes long.

When was this pharmaphorum Podcast episode published?

This episode was published on April 14, 2023.

Can I download this pharmaphorum Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!